Evan Seigerman, BMO, joins ‘Fast Money’ to talk the latest oral obesity treatment data out of Eli Lilly.
Source link
Trending
- Satellite images show Israel building up forces for a possible ground invasion of Gaza, sources say
- SoftBank Group shares surge 13% to a record high after quarterly profit beat estimates
- Tariffs have come — but ‘TACO trade’ seems to be still on
- Market believes Intel -Trump turmoil will pass, says Intelligent Alpha CEO
- We’re itching to buy the dip in our cyber stocks because they shouldn’t be down with the rest
- Instagram’s map feature spurs user backlash over privacy concerns
- Private equity investors want money back but it’s tied up in zombie funds
- Texas Roadhouse’s mixed results capture the conundrum this stock has become
Eli Lilly's oral obesity treatment efficacy falls short of expectations, says BMO's Evan Seigerman
